Regeneron Pharmaceuticals, Inc., a member of The Business Council of Westchester, this week reported strong financial and operating results for the third quarter. Among other signs of growth, the company announced that EYLEA reached over $1 billion in quarterly U.S. net sales and the FDA granted priority review for Dupixent for adolescents.

3Q Highlights:

  • Third quarter 2018